We’ve seen a mix of drug development and health IT out of New England companies this week.
—Best Doctors, a Boston-based company whose database of 50,000 physicians can be called upon to provide second opinions on diagnoses and treatment plans, announced that it had raised $45.5 million in new funding. Brown Brothers Harriman & Co provided the investment, which comes atop $20 million Best Doctors previously raised from firms like Munich Re Group, Coleman Swenson Booth, Polaris Venture Partners, Psilos Group Managers, Southeastern Technology Fund, and Toronto Dominion Partners.
—Cambridge, MA-based Inspiration Biopharmaceuticals restructured a previous licensing, development, and commercialization agreement it had inked with the Paris-based Ipsen Group. Under the new terms, Inspiration sold Ipsen commercialization rights to its two experimental hemophilia drugs in certain geographies, for $30 million upfront. Additional development, commercial, and financing milestones could bring the deal total to $215 million.
—The Boston-based Center for Integration of Medicine and Innovative Technology announced it had teamed up with Norwegian startup Induct Software, whose CEO is Boston-based, to create a Web software platform allowing healthcare institutions across the world to work together to improve patient care.
—My colleague Arlene wrote about EnVivo Pharmaceuticals’ development plans for its experimental alzheimer’s disease treatment. The Watertown, MA-based startup revealed positive data on the drug, EVP-6124, just weeks before Johnson & Johnson and Elan Pharmaceuticals axed the Alzheimer’s drug they were co-developing.
